Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Bayer : fördert freiwilliges Mitarbeiter-Engagement seit zehn Jahren

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/16/2018 | 11:46am CET

Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial: Abstract No: 4501

Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma: Abstract No: 7507

A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome or acute myeloid leukemia: A National Cancer Institute of Cancer Clinical Trials Group Study: Abstract No: 6611

A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer: Abstract No: 3059

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors: Abstract No: 3049

Novel methodology of response assessment in hepatocellular carcinoma - Assessing response by change in tumor enhancement in distinction from conventional means: Abstract No: 3107

Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors: Abstract No: 3056

Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension: Abstract No: 2035

BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience: Abstract No: 7506

Bayer AG published this content on 16 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 16 February 2018 10:45:07 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
02/16BAYER : fördert freiwilliges Mitarbeiter-Engagement seit zehn Jahren
PU
02/15BAYER : Researchers Submit Patent Application, "Antibody and Protein Formulation..
AQ
02/15BAYER : Recent Findings in Pesticides Described by Researchers from Bayer (Refin..
AQ
02/15BAYERNPV : Bayer receives first approval for Eylea in China
AQ
02/15BAYER : Syngenta aims to sell bonds within weeks, M&A important - CFO
RE
02/15BAYER : and Mitsui Chemicals Agro sign licence agreement for novel fungicide
PU
02/14BAYER : Gets FDA Warning Over Manufacturing Practices at German Site
DJ
02/14BAYER : gets FDA rebuke for drug production in Germany
RE
02/14GLOBAL EYE CANCER MARKET REPORT WITH : Global Eye Cancer Market - Global Industr..
AQ
02/14BAYERNPV : Bayer - New data for aflibercept show prolonged injection intervals
AQ
More news
News from SeekingAlpha
02/16Tracking David Einhorn's Portfolio - Q4 2017 Update 
02/15Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q4 2017 Update 
02/14ROAD TO FINANCIAL INDEPENDENCE : My January 88-Stock Portfolio Review 
02/13Bayer sues Russian antitrust regulator in bid for more time in Monsanto case 
02/13YOUR DAILY PHARMA SCOOP : A Look At Celldex, BeiGene Data, Axovant Announces Cha.. 
Financials (€)
Sales 2017 35 346 M
EBIT 2017 7 428 M
Net income 2017 6 815 M
Debt 2017 8 806 M
Yield 2017 2,64%
P/E ratio 2017 13,63
P/E ratio 2018 18,28
EV / Sales 2017 2,55x
EV / Sales 2018 2,50x
Capitalization 81 487 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 121 €
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-6.36%100 998
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572